Navigation Links
Implicit Licenses Clinical Stage Antibody Program From Lilly
Date:2/24/2009

BRISBANE, Australia and SEATTLE, Feb. 24 /PRNewswire/ -- Implicit Bioscience Ltd today announced the acquisition of the clinical-stage monoclonal antibody IC14 from Eli Lilly and Company. Implicit has paid an undisclosed consideration combining cash and stock to Lilly. Lilly will also receive a royalty on future IC14 sales.

"Implicit Bioscience brings substantial expertise and passion to the treatment of patients with immune-mediated disease," commented Professor Ian Frazer FAA, Implicit's Chief Scientific Officer. "We intend to develop this promising drug to treat acute lung injury (ALI) caused by a dysregulated immune response amongst intensive care patients who are on mechanical ventilation. These patients have a significant mortality risk with limited treatment options."

"An effective treatment for ALI has the potential to reduce overall health care costs by allowing the earlier discharge of patients from high-cost intensive care units," Professor Frazer added.

Garry Redlich, Implicit CEO, added, "The transaction to acquire IC14 is a logical and exciting next step in Implicit's business model. We seek to mitigate product risk through acquiring clinical stage programs with proven safety and defined opportunities in immunological indications. We further mitigate risk by seeking non-dilutive third party funding to support a portion of our development expense. We are optimistic that IC14 is an excellent opportunity, and a good fit to our capabilities and business model."

IC14 had earlier been in development for severe sepsis at Icos Corporation which was acquired by Lilly in 2007. It has been used in the treatment of more than 150 patients, and has well characterized safety and pharmacology profiles. Implicit intends to initiate Phase 2 clinical development in ALI during 2009, and recently completed a capital round in which its shareholders added AU$6m to its cash balance.


'/>"/>
SOURCE Implicit Bioscience Ltd
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Implicit Awarded US $16.3 Million U.S. Government Contract to Develop Immunomodulatory Drug for Biodefense Threats
2. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
3. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
4. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
5. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
6. Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
7. Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications
8. HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica
9. Syngenta Licenses Chromatin Gene Stacking Technology
10. Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation
11. Prometheus Licenses COLAL-PRED(R) From Alizyme
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... results of a new study led by George ... evidence that nucleation of ice in small droplets ... water,s behavior at the nanoscale. The formation of ... scientific research question whose answer also has important ... , The crystallization of ice from supercooled water ...
(Date:5/21/2013)... Smarter Security, Inc., provider of premium, innovative ... Genzyme, a Sanofi company and leading biotech company, recently ... a multi-use facility in the United States. With Door ... this latest order underscores the satisfaction and success the ... device improving doorway access control. , “We recommend ...
(Date:5/21/2013)...  MacroGenics, Inc. today announced that an abstract ... Fc-modified chimeric monoclonal antibody (MAb), in patients with ... be presented at the 2013 Annual Meeting of ... Developmental Therapeutics - Immunotherapy Oral Abstract Session on ... The presentation will describe the results of a ...
(Date:5/21/2013)... 21, 2013 NANONEX CORPORATION, a ... , today announced the successful delivery and installation ... the NX-M200B, to a major Japanese manufacturing company. ... fully-automated, production-ready, advanced nanoimprint lithography tool that has ... and substrate sizes and types. Based on Nanonex ...
Breaking Biology Technology:Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing 2
... April 26 Veran Medical Technologies announced today that ... at Duke University Medical Center with its FDA-cleared SPiN ... peripheral regions of the lungs to access, biopsy and treat potentially ... , , ...
... SAN DIEGO , April 26 Santaris ... discovery and development of RNA-targeted therapies, today announced that ... candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), ... cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug ...
... SHANGHAI , April 23 ... today announced that it filed its annual report on Form ... the Securities and Exchange Commission.,The annual report can be accessed ... Relations section. WuXi,PharmaTech will provide a hard copy of its ...
Cached Biology Technology:Veran Medical Technologies' First SPiN Drive Installation at Duke Medical Center 2Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol 2Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol 3Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol 4Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol 5WuXi PharmaTech Files 2009 Annual Report on Form 20-F 2
(Date:5/20/2013)... a compound abundant in the Mediterranean diet takes away ... altering a very specific step in gene regulation, this ... die as scheduled. , One way that cancer cells ... them to die on a regular cycle that is ... by Ohio State University researchers, found that a compound ...
(Date:5/20/2013)... 20, 2013) - A novel vaccine study ... groundbreaking research that will be unveiled at the American ... The meeting takes place Monday, May 20 - Wednesday, ... Marina. , "The main goal of a vaccine ... a pathogen that causes the disease", explained Dr. Hemachand ...
(Date:5/20/2013)... New Geology articles posted online ... cover a wide swath of geoscience subdisciplines, including ... and paleobotany. Locations studied include Siberia; the Sumatran ... Apuane, Italy; Ukraine; Mars; and the Southeastern U.S. ... Rubies, jadeite, and plate tectonics;, 2. The clear ...
Breaking Biology News(10 mins):The compound in the Mediterranean diet that makes cancer cells 'mortal' 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 3Germ-fighting vaccine system makes great strides in delivery 2New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 2New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 3New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 4New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 5New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 6New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 7New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 8New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 9New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 10New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 11
... University of London celebrates distinguished government scientist Professor Robert ... College this week. Chief Scientific Advisor to the ... notable Queen Mary alumnus, Professor Watson is recognised for ... including ozone depletion and global warming. Professor Peter ...
... University researcher has secured a highly sought-after Leadership award which ... Paola Borri, Cardiff School of Biosciences, is a physicist working ... and physical sciences Now, she has won a 1.1M ... the next five years. This will support her own research, ...
... (VBI) at Virginia Tech have constructed a mathematical and ... to simulate the cellular and molecular changes underlying chronic ... to explore different interactions of cells in the immune ... in the colon, and identify intervention points to perhaps ...
Cached Biology News:Honorary Fellowship awarded to government Chief Scientific Advisor 2Boost for world-leading microscopy project 2Math model of colon inflammation singles out dangerous immune cells 2Math model of colon inflammation singles out dangerous immune cells 3
... to 6 strain chambers with precise uniaxial mechanical ... ensures that cells grow over long periods of ... unit allows you to control the frequency and ... strain settings. The instrument fits in a standard ...
... FC 500 Series is a ... the most advanced technologies available. ... flexible testing, powerful software and ... help researchers optimize their overall ...
... using PULSin may be superior to transfection ... traditional transfection, with PULSin you can study ... time course of proteins in cells. Likewise, ... information than traditional RNA interference experiments. ...
... BD FACSVantageTM SE flow cytometry system is ... laboratory. For over 25 years, BD cell ... are found in leading university, pharmaceutical, and ... To meet the research demands of today, ...
Biology Products: